Chronic Lymphocytic Leukemia
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Venetoclax | |
| Sensitivity (+) | TP53 deletion | Chronic Lymphocytic Leukemia | Venetoclax | |
| Sensitivity (+) | 17p deletion | Chronic Lymphocytic Leukemia | Venetoclax | |
| Sensitivity (+) | 17p deletion | Chronic Lymphocytic Leukemia | Venetoclax | |
| Sensitivity (+) | Wild type TP53 | Chronic Lymphocytic Leukemia | Venetoclax | |
| Sensitivity (+) | TP53 deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| Sensitivity (+) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| Sensitivity (+) | 17p deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| Sensitivity (+) | CD20 + | Chronic Lymphocytic Leukemia | Cyclophosphamide, Fludarabine, Rituximab |